Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday, March 15th.
Several other research firms have also recently issued reports on DCPH. B. Riley began coverage on Deciphera Pharmaceuticals in a research note on Friday, February 16th. They issued a “buy” rating and a $43.00 price target for the company. Zacks Investment Research raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research note on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Deciphera Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $41.14.
Shares of NASDAQ:DCPH traded up $2.16 on Thursday, hitting $24.00. The company’s stock had a trading volume of 198,684 shares, compared to its average volume of 107,521. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $29.98. The stock has a market cap of $711.86 and a price-to-earnings ratio of -8.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.35 and a current ratio of 14.35.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Wednesday, March 28th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.19). equities research analysts predict that Deciphera Pharmaceuticals will post -2.36 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in DCPH. Millennium Management LLC lifted its stake in Deciphera Pharmaceuticals by 5.9% in the 4th quarter. Millennium Management LLC now owns 728,583 shares of the company’s stock worth $16,517,000 after acquiring an additional 40,352 shares in the last quarter. TIAA CREF Investment Management LLC acquired a new position in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $257,000. Teachers Advisors LLC acquired a new position in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $332,000. California State Teachers Retirement System acquired a new position in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $295,000. Finally, Deutsche Bank AG acquired a new position in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $410,000. 48.20% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/deciphera-pharmaceuticals-dcph-downgraded-by-bidaskclub-to-buy.html.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.